文献速递结核与非结核分枝杆菌

结核病药物研发中应重视宿主因素

Remembering the Host in Tuberculosis Drug Development.
PubMed 文献 · J Infect Dis · 2019-01-01

本文基于2017年Stop TB新药工作组在意大利卢卡Gordon结核病药物研发会议上的研讨,综述了宿主导向治疗(HDT)用于结核病的新策略。HDT通过激活免疫防御或减轻组织损伤等机制发挥作用,文章强调了成功开发HDT所需关注的药物、通路和概念。

要点

  • HDT是应对耐药结核病的新策略,机制包括激活免疫和减轻组织损伤。
  • 研讨聚焦药物重定位与宿主导向治疗,强调宿主因素在结核药物开发中的重要性。
  • 成功开发HDT需关注特定药物、通路及相关概念的最新数据。

核心结论

  • 宿主导向治疗(HDT)为结核病治疗提供了具有新机制的新策略,有助于应对耐药结核的出现。

研究设计与样本

  • 本文为综述,基于2017年6月在意大利卢卡举行的Gordon结核病药物研发会议中Stop TB新药工作组组织的研讨会内容。

主要发现

  • HDT机制包括激活免疫防御机制或减轻组织损伤。
  • 研讨会讨论了药物重定位与宿主导向治疗用于结核病的战略议题。

临床怎么用

  • 临床应关注HDT作为辅助当前方案、缩短疗程并应对耐药结核的新方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New therapeutics to augment current approaches and shorten treatment duration are of critical importance for combating tuberculosis (TB), especially those with novel mechanisms of action to counter the emergence of drug-resistant TB. Host-directed therapy (HDT) offers a novel strategy with mechanisms that include activating immune defense mechanisms or ameliorating tissue damage. These and related concepts will be discussed along with issues that emerged from the workshop organized by the Stop TB Working Group on New Drugs, held at the Gordon Research Conference for Tuberculosis Drug Development in Lucca, Italy in June 2017, titled "Strategic Discussion on Repurposing Drugs & Host Directed Therapies for TB." In this review, we will highlight recent data regarding drugs, pathways, and concepts that are important for successful development of HDTs for TB.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Frank DJ, Horne DJ, Dutta NK, et al. Remembering the Host in Tuberculosis Drug Development. J Infect Dis. 2019. PMID: 30590592. doi:10.1093/infdis/jiy712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。